questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines de transport
Protéines AAA
ATPases associated with diverse cellular activities
ATP-dependent proteases
ATP-dependent proteases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Angiotensin Receptor Antagonists
Diagnostic
5
Imagerie médicale
Protéases
Symptômes
5
Troubles neurologiques
Protéases
Maladies dégénératives
Inflammation
Douleurs musculaires
Protéines
Prévention
5
Prévention
Alimentation équilibrée
Exercice physique
Santé musculaire
Contrôles médicaux
Protéases
Traitements
5
Suppléments alimentaires
Protéases
Thérapie génique
Protéases
Médicaments anti-inflammatoires
Inflammation
Physiothérapie
Douleurs musculaires
Complications
5
Complications
Maladies dégénératives
Complications cardiovasculaires
Protéases
Système immunitaire
Infections
Troubles neurologiques
Complications
Facteurs de risque
5
Facteurs de risque
Maladies métaboliques
Maladies auto-immunes
Protéases
Stress chronique
Protéases
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "ATP-dependent proteases : Questions médicales les plus fréquentes",
"headline": "ATP-dependent proteases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les ATP-dependent proteases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-23",
"dateModified": "2025-05-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "ATP-dependent proteases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "ATPases associated with diverse cellular activities",
"url": "https://questionsmedicales.fr/mesh/D000074183",
"about": {
"@type": "MedicalCondition",
"name": "ATPases associated with diverse cellular activities",
"code": {
"@type": "MedicalCode",
"code": "D000074183",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.157.025.750"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "ATP-dependent endopeptidases",
"alternateName": "ATP-Dependent Endopeptidases",
"url": "https://questionsmedicales.fr/mesh/D057065",
"about": {
"@type": "MedicalCondition",
"name": "ATP-dependent endopeptidases",
"code": {
"@type": "MedicalCode",
"code": "D057065",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.157.025.750.032.099"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protease La",
"alternateName": "Protease La",
"url": "https://questionsmedicales.fr/mesh/D049070",
"about": {
"@type": "MedicalCondition",
"name": "Protease La",
"code": {
"@type": "MedicalCode",
"code": "D049070",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.157.025.750.032.099.750"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "ATP-dependent proteases",
"alternateName": "ATP-Dependent Proteases",
"code": {
"@type": "MedicalCode",
"code": "D049069",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Zhou Sha",
"url": "https://questionsmedicales.fr/author/Zhou%20Sha",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Case Western Reserve University, Cleveland, Ohio, 44106, USA."
}
},
{
"@type": "Person",
"name": "Jennifer Fishovitz",
"url": "https://questionsmedicales.fr/author/Jennifer%20Fishovitz",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry and Physics, Saint Mary's College, Notre Dame, Indiana, 46556, USA."
}
},
{
"@type": "Person",
"name": "Sujatha Chilakala",
"url": "https://questionsmedicales.fr/author/Sujatha%20Chilakala",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Cleveland State University, Cleveland, Ohio, 44115, USA."
}
},
{
"@type": "Person",
"name": "Yan Xu",
"url": "https://questionsmedicales.fr/author/Yan%20Xu",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Cleveland State University, Cleveland, Ohio, 44115, USA."
}
},
{
"@type": "Person",
"name": "Irene Lee",
"url": "https://questionsmedicales.fr/author/Irene%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Case Western Reserve University, Cleveland, Ohio, 44106, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Synthesis, Characterization and Application of a MIP-polyHIPE for Selective Extraction of Angiotensin II Receptor Antagonists Residues in Natural Waters.",
"datePublished": "2023-03-10",
"url": "https://questionsmedicales.fr/article/36981793",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20064878"
}
},
{
"@type": "ScholarlyArticle",
"name": "Angiotensin receptor blocker use is associated with upregulation of the memory-protective angiotensin type 4 receptor (AT",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/35969296",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11357-022-00639-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Decoding Angiotensin Receptors: TOMAHAQ-Based Detection and Quantification of Angiotensin Type-1 and Type-2 Receptors.",
"datePublished": "2023-09-08",
"url": "https://questionsmedicales.fr/article/37681524",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/JAHA.123.030791"
}
},
{
"@type": "ScholarlyArticle",
"name": "Kidney Outcomes Following Angiotensin Receptor-Neprilysin Inhibitor vs Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy for Thrombotic Microangiopathy.",
"datePublished": "2024-09-03",
"url": "https://questionsmedicales.fr/article/39264627",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.32862"
}
},
{
"@type": "ScholarlyArticle",
"name": "Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction.",
"datePublished": "2022-11-29",
"url": "https://questionsmedicales.fr/article/36459752",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.amjcard.2022.10.026"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines de transport",
"item": "https://questionsmedicales.fr/mesh/D002352"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines AAA",
"item": "https://questionsmedicales.fr/mesh/D000074582"
},
{
"@type": "ListItem",
"position": 6,
"name": "ATPases associated with diverse cellular activities",
"item": "https://questionsmedicales.fr/mesh/D000074183"
},
{
"@type": "ListItem",
"position": 7,
"name": "ATP-dependent proteases",
"item": "https://questionsmedicales.fr/mesh/D049069"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : ATP-dependent proteases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur ATP-dependent proteases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur ATP-dependent proteases",
"description": "Comment diagnostiquer une dysfonction des protéases ATP-dépendantes ?\nQuels tests sanguins sont utiles pour évaluer ces protéases ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nPeut-on utiliser l'imagerie pour diagnostiquer des troubles liés aux protéases ?",
"url": "https://questionsmedicales.fr/mesh/D049069?mesh_terms=Angiotensin+Receptor+Antagonists#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur ATP-dependent proteases",
"description": "Quels sont les symptômes d'une déficience en protéases ATP-dépendantes ?\nLes troubles neurologiques sont-ils liés à ces protéases ?\nComment la dégradation des protéines affecte-t-elle la santé ?\nY a-t-il des signes cutanés associés à ces troubles ?\nLes douleurs musculaires peuvent-elles être un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D049069?mesh_terms=Angiotensin+Receptor+Antagonists#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur ATP-dependent proteases",
"description": "Comment prévenir les troubles liés aux protéases ?\nL'exercice physique joue-t-il un rôle préventif ?\nLes contrôles médicaux réguliers sont-ils importants ?\nY a-t-il des vaccins pour prévenir ces troubles ?\nLe stress peut-il affecter la fonction des protéases ?",
"url": "https://questionsmedicales.fr/mesh/D049069?mesh_terms=Angiotensin+Receptor+Antagonists#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur ATP-dependent proteases",
"description": "Quels traitements existent pour les troubles liés aux protéases ?\nLes suppléments alimentaires peuvent-ils aider ?\nLa thérapie génique est-elle une option ?\nLes médicaments anti-inflammatoires sont-ils utiles ?\nComment la physiothérapie peut-elle aider ?",
"url": "https://questionsmedicales.fr/mesh/D049069?mesh_terms=Angiotensin+Receptor+Antagonists#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur ATP-dependent proteases",
"description": "Quelles complications peuvent survenir avec des troubles protéolytiques ?\nLes complications cardiovasculaires sont-elles possibles ?\nComment les troubles protéolytiques affectent-ils le système immunitaire ?\nY a-t-il un risque accru de cancer ?\nLes troubles neurologiques peuvent-ils s'aggraver ?",
"url": "https://questionsmedicales.fr/mesh/D049069?mesh_terms=Angiotensin+Receptor+Antagonists#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur ATP-dependent proteases",
"description": "Quels sont les facteurs de risque pour les troubles protéolytiques ?\nLe mode de vie influence-t-il ces risques ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?\nL'exposition à des toxines peut-elle augmenter le risque ?",
"url": "https://questionsmedicales.fr/mesh/D049069?mesh_terms=Angiotensin+Receptor+Antagonists#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des protéases ATP-dépendantes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses protéomiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles pour évaluer ces protéases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages d'enzymes spécifiques et des marqueurs de dégradation protéique sont recommandés."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biopsies peuvent aider à évaluer l'activité des protéases dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, la perte de poids et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des troubles liés aux protéases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à visualiser des anomalies tissulaires, mais pas directement les protéases."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en protéases ATP-dépendantes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, troubles digestifs, et accumulation de protéines mal repliées peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés à ces protéases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements peuvent entraîner des troubles neurologiques et cognitifs."
}
},
{
"@type": "Question",
"name": "Comment la dégradation des protéines affecte-t-elle la santé ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une dégradation inappropriée peut mener à des maladies dégénératives et à l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à ces troubles ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des problèmes de cicatrisation peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les douleurs musculaires peuvent-elles être un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent survenir en raison d'une dégradation protéique anormale."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés aux protéases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à maintenir leur fonction."
}
},
{
"@type": "Question",
"name": "L'exercice physique joue-t-il un rôle préventif ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la santé musculaire et enzymatique."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans réguliers peuvent détecter précocement des anomalies protéolytiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir ces troubles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour ces troubles enzymatiques."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter la fonction des protéases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber l'équilibre enzymatique et la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les troubles liés aux protéases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies enzymatiques et des médicaments ciblant les voies protéolytiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les suppléments alimentaires peuvent-ils aider ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains suppléments peuvent soutenir la fonction protéolytique et la santé cellulaire."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est explorée pour corriger des déficiences enzymatiques spécifiques."
}
},
{
"@type": "Question",
"name": "Les médicaments anti-inflammatoires sont-ils utiles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent réduire l'inflammation causée par une dégradation protéique anormale."
}
},
{
"@type": "Question",
"name": "Comment la physiothérapie peut-elle aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La physiothérapie peut améliorer la fonction musculaire et réduire la douleur associée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des troubles protéolytiques ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies dégénératives, des troubles métaboliques et des infections peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications cardiovasculaires sont-elles possibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déséquilibres protéolytiques peuvent contribuer à des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment les troubles protéolytiques affectent-ils le système immunitaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent affaiblir le système immunitaire, rendant l'organisme plus vulnérable aux infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans la dégradation des protéines peuvent être liées à certains cancers."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques peuvent-ils s'aggraver ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles protéolytiques non traités peuvent aggraver les symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles protéolytiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, des antécédents familiaux et des maladies métaboliques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il ces risques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent perturber la fonction des protéases et entraîner des complications."
}
},
{
"@type": "Question",
"name": "Le stress chronique est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la régulation des protéases et la santé globale."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines peut-elle augmenter le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines toxines peuvent altérer la fonction des protéases et causer des dommages cellulaires."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 18/05/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Case Western Reserve University, Cleveland, Ohio, 44106, USA.
Publications dans "ATP-dependent proteases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Physics, Saint Mary's College, Notre Dame, Indiana, 46556, USA.
Publications dans "ATP-dependent proteases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Cleveland State University, Cleveland, Ohio, 44115, USA.
Lawrence J. Ellison Institute for Transformative Medicine of USC, University of Southern California, Beverly Hills, CA, 90211, USA.
Publications dans "ATP-dependent proteases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Cleveland State University, Cleveland, Ohio, 44115, USA.
Publications dans "ATP-dependent proteases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Case Western Reserve University, Cleveland, Ohio, 44106, USA.
Publications dans "ATP-dependent proteases" :
2 publications dans cette catégorie
Affiliations :
Institute of Physics, Chinese Academy of Sciences, Beijing 100190, People's Republic of China.
Publications dans "ATP-dependent proteases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, North-Eastern Hill University, Shillong, 793022, India.
Publications dans "ATP-dependent proteases" :
2 publications dans cette catégorie
Affiliations :
Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Medical Scientist Training Program, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA.
Publications dans "ATP-dependent proteases" :
2 publications dans cette catégorie
Affiliations :
Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA. Craig.Peterson@umassmed.edu.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Department of Agricultural Biotechnology, Center for Food Safety and Toxicology, Center for Food and Bioconvergence, and Research Institute for Agriculture and Life Sciences, CALS, Seoul National University, Seoul 08826, Korea.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Department of Agricultural Biotechnology, Center for Food Safety and Toxicology, Center for Food and Bioconvergence, and Research Institute for Agriculture and Life Sciences, CALS, Seoul National University, Seoul 08826, Korea.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Department of Beauty Care, College of Medical Science, Daegu Haany University, Gyeongsan 38610, Korea.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Department of Agricultural Biotechnology, Center for Food Safety and Toxicology, Center for Food and Bioconvergence, and Research Institute for Agriculture and Life Sciences, CALS, Seoul National University, Seoul 08826, Korea.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Laboratoire de Chimie Bactérienne, UMR 7283, IMM, CNRS, Aix-Marseille Université, Marseille, France.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Plateforme Protéomique de l'IMM, Marseille Protéomique (MaP), CNRS FR 3479, Aix-Marseille Université, Marseille, France.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Laboratoire de Chimie Bactérienne, UMR 7283, IMM, CNRS, Aix-Marseille Université, Marseille, France.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Laboratoire de Chimie Bactérienne, UMR 7283, IMM, CNRS, Aix-Marseille Université, Marseille, France.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Laboratoire de Chimie Bactérienne, UMR 7283, IMM, CNRS, Aix-Marseille Université, Marseille, France. Electronic address: fpompeo@imm.cnrs.fr.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, Michigan State University, East Lansing, Michigan, 48824.
Publications dans "ATP-dependent proteases" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, Michigan State University, East Lansing, Michigan, 48824.
Publications dans "ATP-dependent proteases" :
Polymers via high internal phase emulsion (polyHIPEs) were molecularly imprinted with Irbesartan, an antihypertensive drug belonging to the class of angiotensin II receptor antagonists (sartan drugs),...
The reported primary dementia-protective benefits of angiotensin II type 1 receptor (AT...
Background The renin-angiotensin system plays a crucial role in human physiology, and its main hormone, angiotensin, activates 2 G-protein-coupled receptors, the angiotensin type-1 and type-2 receptor...
Thrombotic microangiopathy (TMA) on kidney biopsy is a pattern of endothelial injury commonly seen in malignant hypertension (mHTN), but treatment strategies are not well established....
To evaluate the kidney outcomes of angiotensin receptor-neprilysin inhibitor (ARNI), specifically sacubitril/valsartan, vs angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocke...
This single-center cohort study enrolled consecutive patients in China diagnosed with mHTN-associated TMA through kidney biopsy from January 2008 to June 2023. Follow-up was conducted until the conclu...
Treatment with sacubitril/valsartan or ACEI/ARBs during hospitalization and after discharge....
The primary outcome was a composite of kidney recovery: a 50% decrease in serum creatinine level, decrease in serum creatinine levels to the reference range, or kidney survival free from dialysis for ...
Among the 217 patients (mean [SD] age, 35.9 [8.8] years; 188 men [86.6%]) included in the study, 66 (30.4%) received sacubitril/valsartan and 151 (69.6%) received ACEI/ARBs at baseline. Sacubitril/val...
In this cohort study, sacubitril/valsartan treatment was associated with a potential kidney function benefit in patients with mHTN-associated TMA compared with ACEI/ARB treatment. The findings suggest...
The superiority of angiotensin receptor-neprilysin inhibitor (ARNI) over angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) has not been reassessed after the public...
Medications used to treat hypertension may affect fracture risk. This study investigated fracture risk for users of angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers ...
Angiotensin receptor blockers (ARBs) used in the treatment of hypertension and potentially in SARS-CoV-2 infection exhibit inverse agonist effects at angiotensin AR1 receptors, suggesting the receptor...
The aim of this study was to conduct a systematic review and meta-analysis to investigate the effect of the premorbid use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker...
Embase, the Cochrane Central Register of Controlled Trials, and MEDLINE were searched for studies based on the below eligibility criteria. The protocol was registered at the PROSPERO (CRD42022309129)....
Eligibility criteria were as follows: (1) randomized controlled trials, cohort studies, cross-sectional studies, (2) patients with sepsis aged ≥16 years, and (3) received premorbid ACEI/ARB, or not....
The patient and study characteristics and outcomes were extracted. All analyses were presented with the use of random-effects models. The primary outcome was short-term mortality defined as ≤30-day, i...
Fifteen studies (N = 96,159) met the eligibility criteria. Of these, eleven studies (N = 40,360) reported unadjusted short-term mortalities. The pooled odds ratio (OR) of short-term mortality with the...
In this meta-analysis, the premorbid ACEI/ARB was associated with significantly lower short-term mortality in patients with sepsis despite the significantly higher risk of AKI....
Guidelines suggest that adults with diabetes and kidney disease receive treatment with angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). This is an update of a Co...
We compared the efficacy and safety of ACEi and ARB therapy (either as monotherapy or in combination) on cardiovascular and kidney outcomes in adults with diabetes and kidney disease....
We searched the Cochrane Kidney and Transplants Register of Studies to 17 March 2024 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register...
We included studies evaluating ACEi or ARB alone or in combination, compared to each other, placebo or no treatment in people with diabetes and kidney disease....
Two authors independently assessed the risk of bias and extracted data. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their...
One hundred and nine studies (28,341 randomised participants) were eligible for inclusion. Overall, the risk of bias was high. Compared to placebo or no treatment, ACEi may make little or no differenc...
ACEi or ARB may make little or no difference to all-cause and cardiovascular death compared to placebo or no treatment in people with diabetes and kidney disease but may prevent kidney failure. ARB ma...
For persons with proteinuria, angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) are treatment mainstays for reducing kidney disease progression. Guidelines f...